NASDAQ:CRSP CRISPR Therapeutics (CRSP) Stock Price, News & Analysis $40.19 +0.04 (+0.10%) Closing price 11/18/2026 04:00 PM EasternExtended Trading$40.84 +0.65 (+1.60%) As of 08:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About CRISPR Therapeutics Stock (NASDAQ:CRSP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRISPR Therapeutics alerts:Sign Up Key Stats Today's Range$40.10▼$42.6650-Day Range$40.15▼$59.0352-Week Range$39.79▼$63.45Volume3.98 million shsAverage Volume1.78 million shsMarket Capitalization$3.90 billionP/E RatioN/ADividend YieldN/APrice Target$72.93Consensus RatingModerate Buy Company Overview CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval. The companies share responsibilities for developing and commercializing Casgevy in authorized markets. Beyond Casgevy, CRISPR Therapeutics is advancing research programs in areas including cancer, autoimmune disease and in vivo gene editing. The company is led by CEO Samarth Kulkarni.AI Generated. May Contain Errors. Read More CRISPR Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScoreCRSP MarketRank™: 2.90627569197 of 5 starsCRISPR Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 765th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCRISPR Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.65, and is based on 2 strong buy ratings, 8 buy ratings, 6 hold ratings, and 1 sell rating.Upside PotentialCRISPR Therapeutics has a consensus price target of $72.93, representing about 81.5% upside from its current price of $40.19.Amount of Analyst CoverageCRISPR Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CRISPR Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CRISPR Therapeutics are expected to grow in the coming year, from ($4.54) to ($3.84) per share.Price to Book Value per Share RatioCRISPR Therapeutics has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.69% of the float of CRISPR Therapeutics has been sold short.Short Interest Ratio / Days to CoverCRISPR Therapeutics has a short interest ratio ("days to cover") of 13.09, which indicates bearish sentiment.Change versus previous monthShort interest in CRISPR Therapeutics has recently increased by 4.54%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCRISPR Therapeutics does not currently pay a dividend.Dividend GrowthCRISPR Therapeutics does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.56 News SentimentCRISPR Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for CRISPR Therapeutics this week, compared to 10 articles on an average week.Search Interest20 people have searched for CRSP on MarketBeat in the last 30 days. This is an increase of 82% compared to the previous 30 days.MarketBeat Follows12 people have added CRISPR Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CRISPR Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,881,663.00 in company stock.Percentage Held by Insiders5.20% of the stock of CRISPR Therapeutics is held by insiders.Percentage Held by Institutions69.20% of the stock of CRISPR Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about CRISPR Therapeutics' insider trading history. Receive CRSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRSP Stock News HeadlinesCRISPR Therapeutics (CRSP) Flags Early CTX310 And Zugo Cel Wins In Two Big MarketsNovember 18 at 7:17 AM | finance.yahoo.comCRISPR Therapeutics (CRSP) Stock Could Be Above Fair Value On Its 50% Five Year FallNovember 18 at 7:17 AM | finance.yahoo.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 19 at 1:00 AM | Behind the Markets (Ad)Is CRISPR Therapeutics (CRSP) Undervalued As CTX310 Data Meets a Share Price Slide?November 18 at 7:17 AM | finance.yahoo.comCRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should KnowNovember 17 at 9:16 AM | finance.yahoo.comSeawolf Therapeutics, Inc. announced that it has received $100 million in funding from a group of investorsNovember 16 at 7:37 AM | marketscreener.comMSeawolf Therapeutics Debuts With $100 Million to Advance DNA-Based TherapeuticsNovember 16 at 7:37 AM | finance.yahoo.comInsider Selling: CRISPR Therapeutics (NASDAQ:CRSP) CEO Sells $2,381,325.86 in StockOctober 21, 2026 | insidertrades.comSee More Headlines CRSP Stock Analysis - Frequently Asked Questions How have CRSP shares performed this year? CRISPR Therapeutics' stock was trading at $52.44 on January 1st, 2026. Since then, CRSP shares have decreased by 23.4% and is now trading at $40.19. How were CRISPR Therapeutics' earnings last quarter? CRISPR Therapeutics AG (NASDAQ:CRSP) issued its quarterly earnings results on Monday, November, 2nd. The company reported ($1.15) EPS for the quarter, missing analysts' consensus estimates of ($1.06) by $0.09. The business's revenue for the quarter was up 1311.1% compared to the same quarter last year. When did CRISPR Therapeutics IPO? CRISPR Therapeutics (CRSP) raised $64 million in an IPO on Wednesday, October 19th 2016. The company issued 4,000,000 shares at a price of $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are CRISPR Therapeutics' major shareholders? Top institutional shareholders of CRISPR Therapeutics include State Street Corp (5.15%), GSK plc (2.69%), Sumitomo Mitsui Trust Group Inc. (1.50%) and Goldman Sachs Group Inc. (0.24%). Insiders that own company stock include Samarth Kulkarni, James R Kasinger, Naimish Patel, Ali Behbahani, Simeon George, Julianne Bruno, John Greene and Raju Prasad. View institutional ownership trends. How do I buy shares of CRISPR Therapeutics? Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CRISPR Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CRISPR Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Micron Technology (MU), Editas Medicine (EDIT) and Block (XYZ). Company Calendar Last Earnings11/02/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6d) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 6 days, CRSP's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CRSP CIK1674416 Webwww.crisprtx.com Phone(617) 315-4600FaxN/AEmployees393Year Founded2013Price Target and Rating Average Price Target for CRISPR Therapeutics$72.93 High Price Target$110.00 Low Price Target$45.00 Potential Upside/Downside+81.5%Consensus RatingModerate Buy Rating Score (0-4)2.65 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($4.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$581.60 million Net Margins-1,812.07% Pretax Margin-1,802.19% Return on Equity-25.59% Return on Assets-17.89% Debt Debt-to-Equity Ratio0.36 Current Ratio16.21 Quick Ratio16.21 Sales & Book Value Annual Sales$3.51 million Price / Sales1,110.66 Cash FlowN/A Price / Cash FlowN/A Book Value$16.99 per share Price / Book2.37Miscellaneous Outstanding Shares97,000,000Free Float91,957,000Market Cap$3.90 billion OptionableOptionable Beta1.92 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:CRSP) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredThe Democrats can’t stop thisPorter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypass...Porter & Company | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredUnbelievable…Congress is About to Do What?Jim Rickards, former advisor to the CIA, the Pentagon and the White House, says a key turning point in Washing...Paradigm Press | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.